Caribou Biosciences, Inc. (CRBU) Stock Score, Valuation & Financial Research
Caribou Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for CRBU
Caribou Biosciences, Inc. currently has a Wall Street Score of 17/100. The stored market price is $1.25. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Caribou Biosciences, Inc. does
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative ag
CRBU financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $1.25
- Market capitalization:
- $124.0M
- Revenue:
- $10.0M
- Net income:
- $-103.4M
- Free cash flow:
- $-112.4M
- Cash:
- $26.2M
- Total debt:
- $26.7M
- EPS:
- -1.08
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-112.4M, showing cash burn in the current stored period.
- The balance sheet shows $26.2M of cash versus $26.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.6 points: CRBU increased 0.6 points because Asset improved by 6.1 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRBU
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.